Back to Search Start Over

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.

Authors :
Awadalla M
Mahmood SS
Groarke JD
Hassan MZO
Nohria A
Rokicki A
Murphy SP
Mercaldo ND
Zhang L
Zlotoff DA
Reynolds KL
Alvi RM
Banerji D
Liu S
Heinzerling LM
Jones-O'Connor M
Bakar RB
Cohen JV
Kirchberger MC
Sullivan RJ
Gupta D
Mulligan CP
Shah SP
Ganatra S
Rizvi MA
Sahni G
Tocchetti CG
Lawrence DP
Mahmoudi M
Devereux RB
Forrestal BJ
Mandawat A
Lyon AR
Chen CL
Barac A
Hung J
Thavendiranathan P
Picard MH
Thuny F
Ederhy S
Fradley MG
Neilan TG
Source :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2020 Feb 11; Vol. 75 (5), pp. 467-478.
Publication Year :
2020

Abstract

Background: There is a need for improved methods for detection and risk stratification of myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain (GLS) is a sensitive marker of cardiac toxicity among patients receiving standard chemotherapy. There are no data on the use of GLS in ICI myocarditis.<br />Objectives: This study sought to evaluate the role of GLS and assess its association with cardiac events among patients with ICI myocarditis.<br />Methods: This study retrospectively compared echocardiographic GLS by speckle tracking at presentation with ICI myocarditis (cases, n = 101) to that from patients receiving an ICI who did not develop myocarditis (control subjects, n = 92). Where available, GLS was also measured pre-ICI in both groups. Major adverse cardiac events (MACE) were defined as a composite of cardiogenic shock, arrest, complete heart block, and cardiac death.<br />Results: Cases and control subjects were similar in age, sex, and cancer type. At presentation with myocarditis, 61 cases (60%) had a normal ejection fraction (EF). Pre-ICI, GLS was similar between cases and control subjects (20.3 ± 2.6% vs. 20.6 ± 2.0%; p = 0.60). There was no change in GLS among control subjects on an ICI without myocarditis (pre-ICI vs. on ICI, 20.6 ± 2.0% vs. 20.5 ± 1.9%; p = 0.41); in contrast, among cases, GLS decreased to 14.1 ± 2.8% (p < 0.001). The GLS at presentation with myocarditis was lower among cases presenting with either a reduced (12.3 ± 2.7%) or preserved EF (15.3 ± 2.0%; p < 0.001). Over a median follow-up of 162 days, 51 (51%) experienced MACE. The risk of MACE was higher with a lower GLS among patients with either a reduced or preserved EF. After adjustment for EF, each percent reduction in GLS was associated with a 1.5-fold increase in MACE among patients with a reduced EF (hazard ratio: 1.5; 95% confidence interval: 1.2 to 1.8) and a 4.4-fold increase with a preserved EF (hazard ratio: 4.4; 95% confidence interval: 2.4 to 7.8).<br />Conclusions: GLS decreases with ICI myocarditis and, compared with control subjects, was lower among cases presenting with either a preserved or reduced EF. Lower GLS was strongly associated with MACE in ICI myocarditis presenting with either a preserved or reduced EF.<br /> (Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-3597
Volume :
75
Issue :
5
Database :
MEDLINE
Journal :
Journal of the American College of Cardiology
Publication Type :
Academic Journal
Accession number :
32029128
Full Text :
https://doi.org/10.1016/j.jacc.2019.11.049